Reports 1H revenue $149,000 vs. $202,000 last year. “Opthea (OPT) is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “Sozinibercept has the potential to be the first product in nearly 20 years to demonstrate superior visual outcomes in combination with standard of care therapy, and we look forward to the anticipated topline data readouts of our two Phase 3 clinical trials in early Q2 and mid-calendar year 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
- Opthea completes drug product PPQ campaign
- Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
- Opthea completes COAST final week 52 patient visit
- Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment